SecBot SecBot

TAK

TAKEDA PHARMACEUTICAL CO LTD
NYSE· Pharmaceutical Preparations· CIK 0001395064 Biotech & Drug Discovery
$21.59 +0.16 (+0.75%)
Nov 16 4:00 PM ET · prev $21.43
Market cap
$66.8B
Large cap
Median target
🔒 Subscribers only
1 year
+52.7%
from $14.14 · Nov 17
30 days
+10.1%
from $19.61
52-week range
$14.06–21.59
at the high
Avg volume 20D
3.02M
shares / day
Short interest
3.07M
≈0.1% of shares · −6.8%
Days to cover
1.0
at average volume
Insider net
−$15.2M
0 buyers · 13 sellers · since Jul 1
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
18
analyzed by SecBot
Congress trades
1
disclosed
SecBot read MIXED 8 reports · 90 days
Balance 1 bearish · 1 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 8/8

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    13 insiders sold $15.2M.

  • InstitutionsBULLISH

    Q3 2026: 34 added (0 new), 11 trimmed or exited.

  • Short sellersSTEADY

    Short interest −6.8% to 3.07M shares. 1.0 days to cover, ≈0.1% of shares.

  • TrendUPTREND

    11% above its 50-day average. New closing high $21.59 on Nov 16.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
Capital Research Global InvestorsADD26,952,673$490.3M
JPMORGAN CHASE & CODOUBLED1,960,697$36.3M
BNP PARIBAS FINANCIAL MARKETSADD1,077,268$19.6M
LPL Financial LLCTRIM361,671$6.6M
Nuveen, LLCADD319,387$5.8M
US BANCORP \DE\TRIM308,078$5.6M
RAYMOND JAMES FINANCIAL INCTRIM297,595$5.4M
Russell Investments Group, Ltd.ADD240,506$4.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action May 2023

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
May 16, 2023TD Cowen
MAINTAIN
MAINTAINOutperform
Apr 4, 2023TD Cowen
MAINTAIN
MAINTAINOutperform
Mar 16, 2023B of A Securities
UPGRADE
UPGRADEBuy
Jul 19, 2022Cowen & Co.
UPGRADE
UPGRADEOutperform
Oct 7, 2021Morgan Stanley
DOWNGRADE
DOWNGRADEEqual-Weight
Mar 11, 2020JP Morgan
MAINTAIN
MAINTAINOverweight
Congressional trades
TAK trades disclosed by members of Congress, with disclosure delay.
1 members · 1 buys / 0 sells
DateMemberType AmountDisclosed
Oct 9, 2026 Ro KhannaDHouse Spouse account · Takeda Pharmaceutical Co Ltd BUY $1K–$15K Nov 5, 2026 +27d

Insider ledger

Form 4
$0
bought · 0 insiders
$15.2M
sold · 13 insiders
DateInsiderTypeValue
Nov 4, 2026
Platford Giles Richard
President, IBU
Nov 4, 2026
SELL$1.2M
Nov 2, 2026
Bitetti Teresa Marie
President, OBU
Nov 2, 2026
SELL$973.7K
Sep 14, 2026
Duprey Lauren Rusckowski
Chief Transformation Officer
Sep 14, 2026
SELL$640.3K
Sep 2, 2026
Plump Andrew Stewart
President, R&D
Sep 2, 2026
SELL$2.1M
Aug 19, 2026
Plump Andrew Stewart
President, R&D
Aug 19, 2026
SELL$363.3K
Aug 18, 2026
Greenway Nicola Deidre Petal
Chief Human Resources Officer
Aug 18, 2026
SELL$235.1K
Aug 11, 2026
Shannon Elaine Mary
Pres., Global Supply & Quality
Aug 11, 2026
SELL$357.4K
Aug 10, 2026
Greenway Nicola Deidre Petal
Chief Human Resources Officer
Aug 10, 2026
SELL$588.7K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

6 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
3,066,552
shares short
-6.8%
vs prior settlement
1.0
days to cover
≈0.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 15, 2026 Clinical trial readout
T-90d Trial Readout: Teduglutide (Phase 3)
Trial: A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome Sponsor: Takeda Phase: Pha
Nov 5, 2026 SEC
Two senior presidents of Takeda sold a combined $2.14M in open-market stock sales over three days, with no 10b5-1…
CLUSTER · Impact 2/10
Nov 4, 2026 Insider
Platford Giles Richard sold 55,617 shares
President, IBU @ $20.90 ($1.2M)
Nov 2, 2026 Insider
Bitetti Teresa Marie sold 46,609 shares
President, OBU @ $20.89 ($973.7K)
Oct 30, 2026 SEC
Giles Richard Platford, President of Takeda's International Business Unit, filed a Form 144 notice of intent to sell…
144 · Impact 2/10
Oct 30, 2026 SEC
Teresa Bitetti, President of Takeda's Global Oncology Business Unit, filed a Form 144 to sell 46,609 American…
144 · Impact 2/10
Oct 9, 2026 Congress
Ro Khanna buy
$1,001 - $15,000 · House
Sep 30, 2026 Inst.
Capital Research Global Investors · ADD
26,952,673 shares ($490.3M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
14 drugs tracked · Drug pipeline →
Recent

SecBot reports

18 filings · 1 bullish · 1 bearish · 1 mixed · 15 neutral
All TAK filing & press-release reports (18)